CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 112 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03708588
NCT03708588Phase 4Completed
CompareCT.gov

Chewed Versus Integral Pill of Ticagrelor in All Patients Undergoing Percutaneous Coronary intervention--a Platelet Reactivity and Patient Outcomes Study.

Wake Forest University Health Sciences·interventional·Posted Oct 17, 2018·Updated Oct 3, 2024

In Brief

A Phase 4 clinical trial evaluating Ticagrelor for Percutaneous Coronary Intervention. Completed, enrolled 112 participants across 1 site.

Detailed Summary

Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPercutaneous Coronary Intervention
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 17, 2018
Enrollment StartSep 19, 2018
Primary CompletionDec 31, 2020
Study CompletionJul 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.7 years ago

Interventions

Ticagrelordrug

Chewed

Ticagrelordrug

Integral